Last reviewed · How we verify
Keith Edwards, M.D. — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Cladribine Tablets | Cladribine Tablets | marketed | Purine nucleoside analog | Ribonucleotide reductase; DNA incorporation | Oncology; Immunology |
Therapeutic area mix
- Oncology; Immunology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Haukeland University Hospital · 1 shared drug class
- M.D. Anderson Cancer Center · 1 shared drug class
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · 1 shared drug class
- Nanfang Hospital, Southern Medical University · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Keith Edwards, M.D.:
- Keith Edwards, M.D. pipeline updates — RSS
- Keith Edwards, M.D. pipeline updates — Atom
- Keith Edwards, M.D. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Keith Edwards, M.D. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/keith-edwards-m-d. Accessed 2026-06-10.